Sanofi and Alnylam to restructure RNAi therapeutics alliance

Sanofi and Alnylam Pharmaceuticals have announced plans to reorganise their RNAi therapeutics rare disease alliance to deliver enhanced benefits and outcomes.

Under the new-look deal, Sanofi will obtain global development and commercialisation rights to fitusiran, an investigational RNAi therapeutic that is currently in development for the treatment of haemophilia A and B.

Global commercialisation of fitusiran will be handled by Sanofi's specialty care global business unit Sanofi Genzyme, with Alnylam to receive sales-based royalties.

Alnylam, meanwhile, will obtain global development and commercialisation rights to investigational RNAi therapeutics programmes for the treatment of ATTR amyloidosis, including patisiran and ALN-TTRsc02, with Sanofi receiving royalties in return.

These changes to the terms of a collaboration first established in 2014 will facilitate the process of bringing these rare disease therapies to market as efficiently as possible.

Bill Sibold, executive vice-president and head of Sanofi Genzyme, said: "This restructuring will enable both parties to maximise the value of each asset and allows us to maintain shared economics across the alliance programme."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.